1 The EIC Accelerator Project
EIC Accelerator Program: An In-Depth OverviewThe EIC Accelerator program, part of the European Innovation Council (EIC), is designed to support small and medium-sized enterprises (SMEs) and startups in developing and scaling innovative technologies in Europe. This program aims to foster the growth of DeepTech companies and facilitate their transition from concept to market-ready solutions. By providing financial support and strategic guidance, the EIC Accelerator enhances the competitiveness of European businesses on a global scale.
Funding Structure: Grant and Equity
The EIC Accelerator offers a unique blended finance model that combines grant funding and equity investment. The grant component can reach up to €2.5 million, aimed at covering costs such as research and development, prototyping, and other early-stage activities crucial for innovation.
In addition to the grant, the program also provides equity financing. From its inception until 2024, companies can secure equity investments of up to €15 million. However, starting from 2025, this equity ceiling will be adjusted to a maximum of €10 million. This funding structure is designed to ensure that businesses have access to sufficient capital to scale operations and bring their products to market, whilst also attracting private investment.
Purpose of the EIC Accelerator
The EIC Accelerator plays a vital role in the European DeepTech and startup ecosystem by targeting high-potential, innovative companies that are often deemed too risky for traditional funding sources. The program not only provides essential financial resources but also connects startups with a network of mentors, industry experts, and potential partners, facilitating knowledge exchange and collaboration. This comprehensive support system empowers companies to overcome challenges, refine their value propositions, and position themselves for commercial success.
Facilitating Scale and Private Funding
By assisting companies in demonstrating technological viability and scalability, the EIC Accelerator enhances their attractiveness to private investors. The program’s rigorous evaluation process, which includes a Step 2 proposal submission followed by a Step 3 interview, ensures that only the most promising projects receive funding. This validation increases investor confidence, making it easier for companies to secure additional funding from private sectors.
Case Study: Inossia AB and the SMART-SOFT Project
Inossia AB, a Swedish company, emerged as a winner of the EIC Accelerator program with its project acronymed SMART-SOFT. The project focuses on the development of the Inossia Cement Softener, a groundbreaking additive for bone cements aimed at revolutionizing the treatment of vertebral fractures in osteoporotic patients. The company submitted its Step 2 proposal on January 11, 2023, later advancing to a successful Step 3 interview.
Technology Basics and Background
The Inossia Cement Softener addresses a critical need in orthopedic medicine, particularly for patients suffering from osteoporosis, a condition that significantly weakens bones and increases fracture risk. Traditional bone cements, while effective, often have limitations in terms of flexibility and adaptability to the unique anatomical needs of osteoporotic fractures.
The innovative cement softener developed by Inossia enhances the properties of existing bone cements, allowing for improved handling and application during surgical procedures. This technology not only facilitates better integration with the surrounding bone tissue but also reduces the risk of complications associated with traditional cements, such as inadequate fixation or excessive stiffness.
By optimizing the mechanical properties of the cement, Inossia's solution promises to improve patient outcomes, potentially leading to quicker recovery times and reduced post-surgical complications. The SMART-SOFT project exemplifies the EIC Accelerator’s mission to support transformative innovations that address significant healthcare challenges, thus contributing to a more robust and effective medical landscape in Europe and beyond.
In summary, the EIC Accelerator program serves as a crucial enabler for startups like Inossia AB, providing them with the necessary resources and support to innovate and scale effectively in the competitive landscape of DeepTech and healthcare solutions.
2 The Funding Rounds
Inossia AB: Financing and Funding Events Since EIC Accelerator Award (2023–2025)
Background:
Inossia AB, a Swedish medtech company specializing in bone cement softeners for improved spinal fracture treatment and active aging, was awarded EIC Accelerator funding following the January 11, 2023, cut-off. The company has since achieved several significant financing milestones.
Financing Raised
Funding Rounds: Timing & Amounts
| Date | Source/Funding Round | Amount Raised | Type |
|---|---|---|---|
| Spring 2023 | EIC Accelerator | €7.3M (€2.3M grant + €5M equity) | Grant + Equity |
| Q2/Q3, 2023 | Private Investment Round | >SEK 10.5M (~€0.9–1M) | Equity |
The exact closing date for the private investment round is not specified but occurred "earlier this spring" by June/July 2023.
Investor Information
- EIC Fund: Lead investor for the equity portion (€5 million).
- Private Investors:
- Majority of existing shareholders participated.
- New investors included:
- ScaleUp Life Science Invest (angel network)
- Svanberg & Co Invest
- Health tech entrepreneur Maria Rankka.
No large institutional VC funds were named; new capital came primarily from angel networks and sector entrepreneurs.
Company Valuations
- As a direct result of securing both public (EIC) and private investments, Inossia’s company valuation increased by SEK 20 million during this period.
- Following these rounds, Inossia’s total value was estimated to exceed SEK 100 million as of mid-2023.
Exit Events: IPOs or Buyouts
As of May 2, 2025:
- There is no record or indication that Inossia AB has undergone an IPO or been acquired.
- No details are available on any planned exit events or secondary offerings up to this date.
Additional Information Related to Funding Rounds
The successful fundraising was attributed in part to: - Recognition from winning highly competitive EU innovation grants (<7% success rate).
The oversubscription signals strong market confidence despite challenging macroeconomic conditions at that time.
In summary:
“With this new capital and the successful investment round, Inossia’s total value is now estimated to exceed SEK100m... The majority of existing shareholders have chosen to join [the] new investors...” — Malin Nilsson, CEO
There have been no indications—publicly available—of further late-stage funding rounds beyond those described above since receiving the initial blended finance package from EIC Accelerator in early-to-mid–2023.
Sources
- Inossia receives higher company valuation and oversubscribes investment round
- GAEU supports Inossia in securing €7.3 MEUR from EIC Accelerator
- Inossia awarded €7.3 Million Euros in funding from European Innovation Council
3 The Press Releases
Inossia AB, a Swedish company, received significant funding from the European Innovation Council (EIC) Accelerator Programme in 2023. This funding was part of the EIC's first 2023 call, which closed on January 11, 2023. Inossia was awarded 7.3 million Euros, consisting of 2.3 million Euros in grant and 5.0 million Euros in equity. This support is crucial for developing and scaling up its innovative bone cement technology, specifically the Inossia Cement Softener, a patented deep-tech innovation.Technology Advancements
The Inossia Cement Softener is designed to make traditional bone cements softer, enhancing their efficiency and safety. This technology opens up new markets and indications, such as treating degenerated discs. With the EIC funding, Inossia plans to clinically validate two new bone cements—V-Flex for spinal fractures and Elastoment for degenerated discs—and obtain regulatory approvals in the EU and US.Partnerships and Funding
The EIC Accelerator Programme provides a blended finance model, combining grants and equity investments to support deep-tech start-ups like Inossia. This funding model is particularly beneficial for companies looking to scale game-changing innovations. Inossia's success in securing this funding highlights the competitive and rigorous selection process of the EIC Accelerator, with less than 7% of all applications being awarded.Team and Company Updates
While specific team updates are not detailed in the available information, the company's achievement in securing EIC funding indicates its strategic positioning and innovation potential in the medical technology sector.Press Releases and Updates
Inossia announced its EIC funding award through its website, highlighting the significance of this support for its future growth and product development. The company's press releases typically focus on major milestones and achievements, such as this funding award, which underscores its commitment to innovation and market expansion.Patents
Inossia's Cement Softener is a patented innovation, indicating the company's focus on protecting its intellectual property and deep-tech advancements.- EIC Accelerator winners and statistics January 2023
- A new group of deep tech start-ups to receive Accelerator investments
4 The Technology Advancements
Inossia AB: Current Capabilities and Advancements
Inossia AB, a Swedish company specializing in vertebral augmentation solutions, has made significant strides since receiving the EIC Accelerator funding in early 2023. The company's primary focus is on developing innovative treatments for osteoporotic fractures, utilizing its patented Inossia Cement Softener technology.
Current Capabilities
Inossia provides solutions tailored to the mechanical properties of brittle osteoporotic bone, offering immediate pain relief and reducing the risk of refractures associated with traditional vertebroplasty and kyphoplasty procedures. Their soft cement technology is designed to adapt bone cements to better match the properties of osteoporotic bone, thereby enhancing treatment outcomes for patients with vertebral fractures.
Advancements Since EIC Accelerator Funding
Following the receipt of €7.3 million in funding from the European Innovation Council (EIC) Accelerator in March 2023, Inossia has been actively engaged in clinically validating its innovative bone cement solutions. This funding, which includes a €2.3 million grant and €5 million in equity, supports the development and market entry of two new bone cements: V-Flex for spinal fractures and Elastoment for degenerated discs.
Inossia is conducting extensive clinical trials, including a large randomized multi-center trial involving 196 participants across nine hospitals in Spain, Poland, Germany, and Canada. The aim of this trial is to demonstrate the efficacy of Inossia's Cement Softener in reducing new fractures compared to traditional bone cement.
Technology Improvements and Market Demonstration
The company has continued to refine its technology, focusing on the adaptability and safety of its soft bone cements. These advancements aim to address significant unmet needs in the treatment of osteoporotic fractures and degenerative disc diseases, offering improved patient outcomes and reduced healthcare costs.
Inossia's soft cement has been positively received in clinical settings, with neurosurgeons noting its ease of use and favorable patient recovery outcomes. The technology has not shown significant differences in surgical technique or complications but has provided early satisfactory pain control and functional recovery.
New Patents, Scientific Studies, and Clinical Trials
While specific details on new patents or whitepapers published since the EIC funding are not readily available, the company's ongoing clinical trials and development of new bone cements (V-Flex and Elastoment) are significant advancements in its technology. These efforts are expected to lead to further publications and regulatory approvals in the future.
Future Prospects
Inossia's focus on innovative solutions for age-related bone conditions positions it as a leader in the MedTech sector. The company's inclusion in reports highlighting next-wave companies in Sweden underscores its potential for growth and impact in the healthcare industry.
Sources:
- Inossia Mentioned as 'Next-wave company' in Sweden
- Inossia: Home
- Inossia company information, funding & investors
- Inossia awarded 7.3 million Euros in funding from the European Innovation Council
- GAEU Consulting - Experts in Horizon Europe funding
5 The Partnerships and Customers
Inossia AB's Strategic Partnerships and Market Positioning Post-EIC Funding Since securing EUR 7.3 million from the European Innovation Council (EIC) Accelerator in early 2023, Inossia AB has strengthened its investor base and clinical trial collaborations while advancing its vertebral augmentation technology.Key Partnerships & Investors
The company's oversubscribed June 2023 investment round brought in ScaleUp Life Science Invest, Svanberg & Co Invest, and health tech entrepreneur Maria Rankka as new investors. This followed Inossia's inclusion in the UIC Accelerator program under Linnéa Capital I, a venture fund supporting Uppsala-based deep-tech startups. While specific customer names remain undisclosed, the company references multiple clinics participating in clinical trials for its bone cement softener.
Purpose of Relationships
Collaborations focus on:
- Clinical validation: Partnering with healthcare providers to demonstrate reduced refracture risk compared to traditional vertebroplasty/kyphoplasty methods
- Regulatory compliance: Strengthening quality systems for CE marking through project-specific expertise (e.g., Vinnova-funded initiatives)
- Market expansion: Leveraging EIC networks for pan-European commercialization of its osteoporosis treatment solutions
Market Positioning & Technology Impact
The EIC funding and investor partnerships enable:
Recent April 2025 updates confirm continued progress through internal financing rounds, though no additional external partners beyond those disclosed post-EIC have been formally announced. The company maintains focus on translating capital injections into clinical adoption pathways across European markets.
Sources Used
- Inossia Receives Higher Valuation - June 2023 funding details
- Inossia AB Website - Product specifications and trial references
- Swecris Project Page - Regulatory development insights
- UIC Annual Review 2023 - Linnéa Capital partnership context
6 The Hiring and Company Growth
Inossia AB: Growth and Developments Since EIC Accelerator Funding
Inossia AB, a Swedish company, received significant funding from the European Innovation Council (EIC) Accelerator Programme in January 2023. Since then, the company has continued to advance its innovative solutions for vertebral augmentation, focusing on improving treatments for osteoporotic fractures.
Current Headcount and Team Size
As of now, specific details regarding the current headcount or team size of Inossia AB are not publicly available. However, the company's growth and ongoing clinical trials indicate an expansion in their operations.
Hiring and Team Growth
Inossia is likely to be hiring professionals to support their clinical trials and product development. With the EIC funding, they are enhancing their capabilities, which may require additional talent in medical research, clinical trials management, and regulatory affairs.
Recent Growth
Since receiving the EIC funding, Inossia has been able to further develop two new bone cements—V-Flex for spinal fractures and Elastoment for degenerated discs. This funding has also enabled them to pursue regulatory approvals in the EU and US, marking significant progress in their growth strategy.
Key Positions and New Team Members
While specific key positions recently hired are not detailed, the company's expansion into new product categories and regulatory processes likely involves hiring experienced professionals in these areas. These new team members will be crucial for scaling and growing the company, particularly in managing clinical trials and navigating regulatory approvals.
Future Impact
The addition of new team members and the development of new products will be pivotal for Inossia's future. These advancements will help the company address unmet needs in osteoporotic fracture treatments and degenerative disc diseases, positioning them for significant market impact and growth. The new products and expanded team will facilitate Inossia's goal of reducing refracture risks and improving patient outcomes, contributing to active aging and reduced healthcare costs.
Management and Founding Team Changes
There is no specific information available regarding major changes in management or the founding team since the EIC Accelerator funding. However, CEO Malin Nilsson has been actively involved in promoting the company's innovations and strategic developments.
Sources
- Inossia: Home
- Inossia awarded 7.3 million Euros in funding from the European Innovation Council (EIC) Accelerator Programme
7 The Media Features and Publications
Inossia AB: Recent Developments and Activities
Inossia AB, a Swedish MedTech company, has garnered significant attention since receiving funding from the European Innovation Council (EIC) Accelerator Programme in early 2023. Here's an overview of the media features, publications, and events involving Inossia:
Media Features and Publications
- EIC Accelerator Funding: In March 2023, Inossia was awarded €7.3 million, comprising a €2.3 million grant and €5 million in equity, to develop innovative bone cements using the patented Inossia Cement Softener technology.
- Recognition as a Next-wave Company: In February 2025, Inossia was recognized as one of the next-wave companies in MedTech by Industrifonden, highlighting its potential in the Swedish deep-tech landscape.
Podcasts and Interviews
Currently, there is no publicly available information on specific podcasts or interviews featuring the Inossia team.
Conference and Fair Visits
- Interdisciplinary Research Conference (Griboi): In October 2023, Inossia participated in the Griboi conference in Solothurn, Switzerland, where CEO Malin Nilsson presented on disc augmentation with PMMA bone cement and showcased the V-Flex flexible bone cement.
- Medicon Village Membership: Inossia joined the Medicon Village, further integrating with the Swedish life sciences community.
Event Participation
- IVA 104th Anniversary Gathering: In February 2024, Inossia was present at this event, emphasizing its engagement with Swedish innovation communities.
- Congress in Frankfurt: In October 2023, Inossia attended a congress in Frankfurt, expanding its international presence in the MedTech sector.
Involvement in Events
Inossia actively participates in various conferences and gatherings to showcase its innovative medical technologies and collaborate with experts in the field.
Sources: - Inossia Awarded 7.3 Million Euros in Funding from the European Innovation Council
- Inossia Mentioned as 'Next-wave company' in Sweden
- Inossia at GRIBOI in Solothurn, Switzerland
- News - Inossia
Do you need EIC Accelerator support?
Here is a list of the key service options for the EIC Accelerator:
Full Writing Service
All proposal sections are written by Stephan Segler, PhD.
Advisory Service
You write in-house but receive 1-on-1 support, templates, instructions, and reviews of all documents.
AI Writer & Training
A high-quality AI writer for EIC Accelerator Step 1 and a comprehensive Training program for Steps 1 and 2 including all templates and instructions.